Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Barros‐Martins, Joana; I. Hammerschmidt, Swantje; Cossmann, Anne; Odak, Ivan; V. Stankov, Metodi; Morillas Ramos, Gema; Dopfer‐Jablonka, Alexandra; Heidemann, Annika; Ritter, Christiane; Friedrichsen, Michaela; Schultze‐Florey, Christian; Ravens, Inga; Willenzon, Stefanie; Bubke, Anja; Ristenpart, Jasmin; Janssen, Anika; Ssebyatika, George; Bernhardt, Günter; Münch, Jan; Hoffmann, Markus; Pöhlmann, Stefan; Krey, Thomas; Bošnjak, Berislav; Förster, Reinhold; M. N. Behrens, Georg

doi:10.1038/s41591-021-01449-9

Public

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Published in Nature Medicine • Jul 14, 2021

Authors:

Joana Barros‐Martins

Swantje I. Hammerschmidt

Anne Cossmann

Abstract

Abstract Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) o...

Subject

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Coronavirus disease 2019 (COVID-19)

Heterologous

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!